Why the study?
Does dual energy SPECT using new radiopharmaceuticals provide precise characterization of myocardial viability in coronary artery disease?
Does dual energy SPECT using new radiopharmaceuticals provide precise characterization of myocardial viability in coronary artery disease?
Dual energy SPECT with novel radiopharmaceuticals allows for detailed assessment of myocardial viability, metabolism, and sympathetic nerve activity in coronary artery disease.
Answers are grounded in this paper and cite their sources.
May support viability assessment in CAD; leaves open clinical adoption pending prospective validation.
Thallium myocardial imaging has been widely available for the detection of myocardial ischemia and assessment of myocardial viability in coronary artery diseases. However, myocardial imaging using SPECT and gamma-emitting radiopharmaceuticals has been developed for accurate evaluation of myocardial infarction and ischemia. The present study was undertaken to clinically evaluate myocardial necrosis, metabolism and sympathetic nerve activity. In this study, myocardial fatty acid metabolism was assessed using 123I-BMIPP, myocardial sympathetic neural activity was assessed using 123I-MIBG and myocardial necrosis was assessed using 111-In-antimyosin Fab. Dual energy SPECT using these new agents and thallium gives precise characterization of myocardial viability in coronary artery disease.
No takes yet. Share an insight, caveat, or question.
NISHIMURA et al. (1992) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: